Wang John Q, Guo Ming-Lei, Jin Dao-Zhong, Xue Bing, Fibuch Eugene E, Mao Li-Min
Department of Basic Medical Science, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA; Department of Anesthesiology, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA.
Department of Basic Medical Science, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA.
Eur J Pharmacol. 2014 Apr 5;728:183-7. doi: 10.1016/j.ejphar.2013.11.019. Epub 2013 Nov 28.
Protein phosphorylation is an important mechanism for regulating ionotropic glutamate receptors (iGluRs). Early studies have established that major iGluR subtypes, including α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors and N-methyl-d-aspartate (NMDA) receptors, are subject to phosphorylation. Multiple serine, threonine, and tyrosine residues predominantly within the C-terminal regions of AMPA receptor and NMDA receptor subunits have been identified as sensitive phosphorylation sites. These distinct sites undergo either constitutive phosphorylation or activity-dependent phosphorylation induced by changing cellular and synaptic inputs. An increasing number of synapse-enriched protein kinases have been found to phosphorylate iGluRs The common kinases include protein kinase A, protein kinase C, Ca(2+)/calmodulin-dependent protein kinase II, Src/Fyn non-receptor tyrosine kinases, and cyclin dependent kinase-5. Regulated phosphorylation plays a well-documented role in modulating the biochemical, biophysical, and functional properties of the receptor. In the future, identifying the precise mechanisms how phosphorylation regulates iGluR activities and finding the link between iGluR phosphorylation and the pathogenesis of various brain diseases, including psychiatric and neurodegenerative diseases, chronic pain, stroke, Alzheimer's disease and substance addiction, will be hot topics and could contribute to the development of novel pharmacotherapies, by targeting the defined phosphorylation process, for suppressing iGluR-related disorders.
蛋白质磷酸化是调节离子型谷氨酸受体(iGluRs)的重要机制。早期研究已证实,包括α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)受体和N-甲基-D-天冬氨酸(NMDA)受体在内的主要iGluR亚型都可发生磷酸化。已确定AMPA受体和NMDA受体亚基的C末端区域内的多个丝氨酸、苏氨酸和酪氨酸残基为敏感磷酸化位点。这些不同的位点会经历组成型磷酸化或由细胞和突触输入变化诱导的活性依赖性磷酸化。越来越多富含突触的蛋白激酶被发现可使iGluRs磷酸化。常见的激酶包括蛋白激酶A、蛋白激酶C、钙/钙调蛋白依赖性蛋白激酶II、Src/Fyn非受体酪氨酸激酶和细胞周期蛋白依赖性激酶-5。调节性磷酸化在调节受体的生化、生物物理和功能特性方面发挥着有据可查的作用。未来,确定磷酸化如何调节iGluR活性的确切机制,以及找到iGluR磷酸化与包括精神疾病和神经退行性疾病、慢性疼痛、中风、阿尔茨海默病和药物成瘾在内的各种脑部疾病发病机制之间的联系,将成为热门话题,并可能通过针对特定的磷酸化过程来开发新型药物疗法,以抑制与iGluR相关的疾病。